lomustine has been researched along with Metastase in 85 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma." | 9.11 | Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. ( Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005) |
| "A Phase II trial comprising patients with metastatic uveal melanoma (Stage IVB) was undertaken to determine the activity of bleomycin, vincristine, lomustine, and dacarbazine (BOLD) chemotherapy with human leukocyte interferon, as well as the progression-free and overall survival of the patients according to the substage before treatment." | 9.10 | Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. ( Eskelin, S; Hahka-Kemppinen, M; Kivelä, T; Muhonen, T; Nikkanen, V; Pyrhönen, S; Summanen, P; Tarkkanen, A, 2002) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 9.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 9.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 7.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "Forty-six consecutive, evaluable patients with a diagnosis of metastatic melanoma without prior chemotherapy were treated with bleomycin, vincristine, lomustine, and DTIC (BOLD)." | 7.67 | Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. ( Foltz, AT; York, RM, 1988) |
| "Twenty-one patients with Stage III malignant melanoma have been treated with a 5-day quadruple chemotherapy regime (BELD) comprising bleomycin 15 mg subcutaneously on days 1 and 4, vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 intravenously on days 1 through 5." | 7.67 | The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. ( English, JS; Lever, RS; MacKie, RM; Young, DW, 1985) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 7.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 7.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| "This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b." | 6.71 | Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. ( Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS, 2003) |
| "This randomized phase II study was designed to compare the efficacy and tolerability of dacarbazine (DTIC) and bleomycin, vincristine, lomustine and DTIC (BOLD) combined with natural interferon-alpha (nIFN-alpha) or recombinant interferon-alpha2b (rIFN-alpha2b) in patients with advanced melanoma." | 5.11 | Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. ( Hahka-Kemppinen, M; Kellokumpu-Lehtinen, P; Korpela, M; Parvinen, LM; Pyrhönen, S; Seppä, H; Vuoristo, MS, 2005) |
| "A Phase II trial comprising patients with metastatic uveal melanoma (Stage IVB) was undertaken to determine the activity of bleomycin, vincristine, lomustine, and dacarbazine (BOLD) chemotherapy with human leukocyte interferon, as well as the progression-free and overall survival of the patients according to the substage before treatment." | 5.10 | Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. ( Eskelin, S; Hahka-Kemppinen, M; Kivelä, T; Muhonen, T; Nikkanen, V; Pyrhönen, S; Summanen, P; Tarkkanen, A, 2002) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 5.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Thirty-seven consecutive patients with disseminated malignant melanoma and previously untreated with chemotherapy were randomly allocated to receive vindesine, cis-platinum, and etoposide (Regimen A) or vindesine, cis-platinum, and lomustine (Regimen B)." | 5.05 | Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine. ( Bajetta, E; Bonadonna, G; Buzzoni, R; Nava, M; Vaglini, M; Viviani, S, 1985) |
| "Forty-three patients with inoperable and/or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl) -3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m2 for two days)." | 5.04 | [Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial]. ( Buge, A; Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, HT, 1976) |
| "Forty-three patients with inoperable and/or recurring malignant gliomas and 30 patients with multiple recurring brain metastases were treated with a combination of adriamycine (45 mg/m 2 and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m 2 for 2 days) and 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea (CCNU) (60 mg/m 2 for 2 days)." | 5.04 | Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial. ( Gautier, H; Huguenin, P; Lheritier, J; Mathé, G; Morin, P; Palangie, T; Parrot, R; Poisson, M; Pouillart, P, 1977) |
| "As reported earlier, a chemotherapy regimen that consisted of dacarbazine, vincristine, lomustine, and bleomycin (DOBC) combined with natural leukocyte interferon (IFN) has been administered with favorable results to patients with metastatic melanoma." | 3.69 | The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. ( Hahka-Kemppinen, M; Hernberg, M; Muhonen, T; Pyrhönen, S; Turunen, JP, 1996) |
| "In a consecutive series of studies, 164 patients with symptomatic and/or visceral metastatic malignant melanoma were treated with single agent vindesine, high dose melphalan with autologous bone marrow transplantation (AMBT), high dose BCNU with ABMT or the BOLD (bleomycin, vincristine, CCNU and DTIC) combination." | 3.68 | Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit. ( Bliss, JM; Gore, ME; Lakhani, S; McElwain, TJ; Perren, TJ; Selby, P, 1990) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 3.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "Forty-six consecutive, evaluable patients with a diagnosis of metastatic melanoma without prior chemotherapy were treated with bleomycin, vincristine, lomustine, and DTIC (BOLD)." | 3.67 | Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. ( Foltz, AT; York, RM, 1988) |
| "Twenty-one patients with Stage III malignant melanoma have been treated with a 5-day quadruple chemotherapy regime (BELD) comprising bleomycin 15 mg subcutaneously on days 1 and 4, vindesine (Eldesine) 3 mg/m2 intravenously on days 1 and 5, CCNU (lomusine) 80 mg/m2 orally on day 1, and DTIC 200 mg/m2 intravenously on days 1 through 5." | 3.67 | The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma. ( English, JS; Lever, RS; MacKie, RM; Young, DW, 1985) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 3.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Sixty patients with renal adenocarcinoma have been treated with five different immunotherapy trials consisting of 1) Transfer Factor (TF), 2) TF and Bacillus Calmette-Guerin (BCG), 3) TF, BCG, Chloroethyl-cyclohexy-nitrosurea (CCNU) and megestrol acetate (Megase), 4) BCG, CCNU, and Megase, or 5) BCG." | 3.66 | A critical review of immunotherapy of disseminated renal adenocarcinoma. ( Bukowski, RM; James, RE; Montie, JE; Stewart, BH; Straffon, RA, 1982) |
| "Twelve previously untreated patients with histologically documented, metastatic, malignant melanoma were treated with the combination of procarbazine, vincristine, CCNU, and cyclophosphamide, with an objective response rate of 33%." | 3.66 | Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma. ( Dillman, RO; Green, MR; Horton, C, 1980) |
| "Forty-three patients with inoperable or recurring malignant gliomas, and 30 patients with multiple recurring brain metastases were treated with a combination of Adriamycin (45 mg/m2) and 4-dimethyl-epipodophyllotoxin D-thenylidene (VM 26) (60 mg/m2 for 2 days) with 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) (60 mg/m2 for 2 days)." | 3.65 | Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail. ( Gauthier, H; Huguenin, P; Lheritier, J; Mathe, G; Morin, P; Parrot, R; Poisson, M; Pouillart, P; Thy, TH, 1976) |
| "A median of two cycles were given until disease progression or grade 3/4 toxicity." | 2.71 | Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial. ( Neville, F; Nystrom, ML; Oliver, RT; Shamash, J; Steele, JP, 2003) |
| "This EORTC multicentre study analysed the efficacy and tolerability in patients with metastatic uveal melanoma of BOLD chemotherapy in combination with recombinant interferon alpha-2b." | 2.71 | Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. ( Gore, M; Hahka-Kemppinen, M; Hansson, J; Humblet, Y; Kivelä, T; Kloke, O; Kruit, WH; Kumpulainen, E; Parvinen, LM; Pyrhönen, S; Suciu, S; Vuoristo, MS, 2003) |
| "The distant metastasis rate was significantly lower in group B (P less than ." | 2.67 | Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. ( Arriagada, R; Douillard, JY; Lacombe-Terrier, MJ; Laplanche, A; Le Chevalier, T; Martin, M; Quoix, E; Ruffie, P; Tarayre, M, 1991) |
| "Forty-six adult patients with colorectal cancer were treated with cyclophosphamide and CCNU administered orally and 5-fluorouracil (5-FU) administered either orally or by continuous iv infusion (FCC-CIF), depending on the availability of hospital beds." | 2.64 | Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil. ( Bedikian, AY; Bodey, GP; Burgess, MA; Livingston, R; Staab, R; Valdivieso, M, 1978) |
| "Brain metastasis occurred in 0/14 patients in the PCI and 4/15 in the non-PCI (P less than or equal to ." | 2.64 | Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study. ( Cooper, MR; Ferree, C; Jackson, DV; Muss, HB; Richards, F; Spurr, CL; White, DR, 1977) |
| "Pituitary tumors are mostly benign lesions, although 5-35% are locally invasive." | 1.30 | The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors. ( Besser, GM; Grossman, AB; Kaltsas, GA; Monson, JP; Mukherjee, JJ; Plowman, PN, 1998) |
| "Six of them had tumor metastasis with in 6 months after the initial treatment(s)." | 1.27 | [Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma]. ( Matsumoto, S; Oi, S; Raimondi, AJ, 1985) |
| " The therapy is to be used effectfully only then, when indication, dosage and control of the patients are performed critically and exactly." | 1.26 | [Chemotherapy of malignant solid tumors]. ( Knöll, P; Siering, H, 1980) |
| "One patient with gastric cancer attained a partial remission with a duration of remission of 9." | 1.26 | [Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract]. ( Hartmann, D; Obrecht, JP; Stalder, GA, 1978) |
| "Three patients developed CNS metastasis while on treatment." | 1.26 | Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Hortobagyi, GN; Tashima, CK; Waterfield, WC, 1978) |
| " Data from other centers have shown that augmentation of remissions for melanoma patients occurred when BCG was combined with DTIC, vincristine, and allogeneic tumor cells." | 1.26 | Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. ( Burgess, MA; Gottlieb, J; Gutterman, JU; Hersh, EM; Mavligit, GM; Reed, R, 1976) |
| "Untreated meningeal carcinomatosis is a uniformly fatal type of metastatic disease presenting with many protean signs and symptoms." | 1.26 | Meningeal carcinomatosis. Case report and review of the literature. ( Bender, J; Bramlet, D; Giliberti, J, 1976) |
| "Distant metastases were more frequent in the R series, being reported in 99 (82%) compared with 82 (71%) of the RC patients (P less than 0." | 1.26 | Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung: the results at 36 months. 2nd report to the Medical Research Council on the 2nd small-cell study. ( , 1981) |
| "Hypercalcemia is very uncommon in small cell (oat cell) carcinoma of the lung." | 1.25 | Hypercalcemia in small cell (oat cell) carcinoma of the lung. Coincident parathyroid adenoma in one case. ( Bowman, DM; Dubé, WJ; Levitt, M, 1975) |
| "The growth rate of spherical pulmonary metastases was studied in 15 patients with osseous and soft tissue sarcoma." | 1.25 | Growth rate of pulmonary metastases in human sarcomas. ( Band, PR; Kocandrle, C, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 67 (78.82) | 18.7374 |
| 1990's | 10 (11.76) | 18.2507 |
| 2000's | 6 (7.06) | 29.6817 |
| 2010's | 2 (2.35) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taylor, RE | 1 |
| Howman, AJ | 1 |
| Wheatley, K | 1 |
| Brogden, EE | 1 |
| Large, B | 1 |
| Gibson, MJ | 1 |
| Robson, K | 1 |
| Mitra, D | 1 |
| Saran, F | 1 |
| Michalski, A | 1 |
| Pizer, BL | 1 |
| Buzás, K | 1 |
| Marton, A | 1 |
| Vizler, C | 1 |
| Gyukity-Sebestyén, E | 1 |
| Harmati, M | 1 |
| Nagy, K | 1 |
| Zvara, Á | 1 |
| Katona, RL | 1 |
| Tubak, V | 1 |
| Endrész, V | 1 |
| Németh, IB | 1 |
| Oláh, J | 1 |
| Vígh, L | 1 |
| Bíró, T | 1 |
| Kemény, L | 1 |
| Fewer, D | 1 |
| Wilson, CB | 2 |
| Boldrey, EB | 2 |
| Enot, JK | 1 |
| Skorupski, KA | 1 |
| Rodriguez, CO | 1 |
| Krick, EL | 1 |
| Clifford, CA | 1 |
| Ward, R | 1 |
| Kent, MS | 1 |
| Pyrhönen, S | 6 |
| Hahka-Kemppinen, M | 5 |
| Muhonen, T | 4 |
| Nikkanen, V | 1 |
| Eskelin, S | 1 |
| Summanen, P | 1 |
| Tarkkanen, A | 1 |
| Kivelä, T | 2 |
| Nystrom, ML | 1 |
| Steele, JP | 1 |
| Shamash, J | 1 |
| Neville, F | 1 |
| Oliver, RT | 1 |
| Suciu, S | 1 |
| Hansson, J | 1 |
| Kruit, WH | 1 |
| Vuoristo, MS | 3 |
| Kloke, O | 1 |
| Gore, M | 1 |
| Parvinen, LM | 2 |
| Kumpulainen, E | 3 |
| Humblet, Y | 1 |
| Lens, MB | 1 |
| Eisen, TG | 1 |
| Seppä, H | 1 |
| Korpela, M | 3 |
| Kellokumpu-Lehtinen, P | 2 |
| Siering, H | 1 |
| Knöll, P | 1 |
| Kelsen, D | 1 |
| Osterlind, K | 2 |
| Sörenson, S | 1 |
| Hansen, HH | 2 |
| Dombernowsky, P | 1 |
| Hirsch, FR | 1 |
| Hansen, M | 2 |
| Rørth, M | 1 |
| Bernengo, MG | 1 |
| Lisa, F | 1 |
| Meregalli, M | 1 |
| Doveil, GC | 1 |
| Ojala, A | 1 |
| Nikkanen, VN | 1 |
| Paloheimo, S | 1 |
| Palojoki, A | 1 |
| Thölix, E | 1 |
| Xavier, AM | 1 |
| Kasimis, BS | 1 |
| Wu, SY | 1 |
| Kaneshiro, CA | 1 |
| Chahinian, AP | 1 |
| Green, G | 1 |
| Holland, JF | 2 |
| Carmo-Pereira, J | 1 |
| Costa, FO | 1 |
| Henriques, E | 1 |
| Montie, JE | 1 |
| Bukowski, RM | 1 |
| James, RE | 1 |
| Straffon, RA | 1 |
| Stewart, BH | 1 |
| Green, MR | 1 |
| Dillman, RO | 1 |
| Horton, C | 1 |
| Tirelli, U | 1 |
| Frustaci, S | 1 |
| Galligioni, E | 1 |
| Veronesi, A | 1 |
| Trovò, MG | 1 |
| Magri, DM | 1 |
| Crivellari, D | 1 |
| Roncadin, M | 1 |
| Tumolo, S | 1 |
| Grigoletto, E | 1 |
| Vuoristo, M | 1 |
| Gröhn, P | 2 |
| Turunen, M | 1 |
| Joensuu, H | 1 |
| Tiusanen, K | 1 |
| Nevantaus, A | 1 |
| Samuel, LM | 1 |
| Harvey, VJ | 1 |
| Mitchell, PL | 1 |
| Thompson, PI | 1 |
| Mak, D | 1 |
| Melville, P | 1 |
| Evans, BD | 1 |
| Hernberg, M | 2 |
| Turunen, JP | 2 |
| Kangas, L | 1 |
| Kaltsas, GA | 1 |
| Mukherjee, JJ | 1 |
| Plowman, PN | 1 |
| Monson, JP | 1 |
| Grossman, AB | 1 |
| Besser, GM | 1 |
| Brunner, KW | 1 |
| Sonntag, RW | 1 |
| Cannon, PJ | 1 |
| Wajsman, Z | 1 |
| Baumgartner, G | 1 |
| Merrin, C | 1 |
| Folke, E | 1 |
| Per, J | 1 |
| Britta, W | 1 |
| De Wasch, G | 1 |
| Bernheim, J | 1 |
| Michel, J | 2 |
| Lejeune, F | 1 |
| Kenis, Y | 2 |
| Hahn, DM | 1 |
| Schimpff, SC | 1 |
| Ruckdeschel, JC | 1 |
| Wiernik, PH | 1 |
| Richards, F | 2 |
| Muss, HB | 2 |
| White, DR | 2 |
| Cooper, MR | 2 |
| Spurr, CL | 2 |
| Band, PR | 2 |
| Canellos, GP | 1 |
| Sears, M | 1 |
| Israel, L | 1 |
| Pocock, SJ | 1 |
| Everall, JD | 1 |
| Dowd, PM | 1 |
| Moertel, CG | 1 |
| Engstrom, P | 1 |
| Lavin, PT | 1 |
| Gelber, RD | 1 |
| Carbone, PP | 1 |
| Bowman, DM | 1 |
| Dubé, WJ | 1 |
| Levitt, M | 1 |
| Williams, CJ | 1 |
| Vosika, GJ | 2 |
| Panettiere, FJ | 1 |
| Mulder, JH | 1 |
| Smink, T | 1 |
| Van Putten, LM | 1 |
| Valdivieso, M | 2 |
| Bedikian, A | 1 |
| Burgess, MA | 4 |
| Rodriguez, V | 1 |
| Hersh, EM | 2 |
| Bodey, GP | 2 |
| Mavligit, GM | 2 |
| Pouillart, P | 3 |
| Mathé, G | 3 |
| Palangie, T | 1 |
| Lheritier, J | 3 |
| Poisson, M | 3 |
| Huguenin, P | 3 |
| Gautier, H | 2 |
| Morin, P | 3 |
| Parrot, R | 3 |
| Paoletti, P | 1 |
| Robustelli della Cuna, G | 1 |
| Knerich, R | 1 |
| Strada, MR | 1 |
| Bedikian, AY | 1 |
| Staab, R | 1 |
| Livingston, R | 1 |
| Hartmann, D | 1 |
| Obrecht, JP | 1 |
| Stalder, GA | 1 |
| Ryan, MJ | 1 |
| Fortuny, IA | 1 |
| Meyer, C | 1 |
| Kiang, DT | 1 |
| Theologides, A | 1 |
| Kennedy, BJ | 1 |
| Hasegawa, H | 1 |
| Shapiro, WR | 1 |
| Posner, JB | 1 |
| Jackson, DV | 1 |
| Ferree, C | 1 |
| Waterfield, WC | 1 |
| Tashima, CK | 1 |
| Hortobagyi, GN | 1 |
| Blumenschein, GR | 1 |
| Buzdar, AU | 1 |
| Comis, RL | 1 |
| Gutterman, JU | 1 |
| Reed, R | 1 |
| Gottlieb, J | 1 |
| Cedermark, BJ | 1 |
| Didolkar, MS | 1 |
| Elias, EG | 1 |
| Buge, A | 1 |
| Thy, HT | 1 |
| Levin, VA | 1 |
| Wilson, WL | 1 |
| Andrews, NC | 1 |
| Frelick, RW | 1 |
| Nealon, TF | 1 |
| Bick, RL | 1 |
| Adams, T | 1 |
| Aranha, GV | 1 |
| Grage, TB | 1 |
| Tejada, F | 1 |
| Eisenberger, MA | 1 |
| Broder, LA | 1 |
| Cohen, MH | 1 |
| Simon, R | 1 |
| Palshof, T | 1 |
| Mouridsen, H | 1 |
| Bramlet, D | 1 |
| Giliberti, J | 1 |
| Bender, J | 1 |
| Mannes, P | 1 |
| Derriks, R | 1 |
| Moens, R | 1 |
| Laurent, C | 1 |
| Thy, TH | 1 |
| Gauthier, H | 1 |
| Kocandrle, C | 1 |
| Gutin, PH | 1 |
| Kumar, AR | 1 |
| Levin, V | 1 |
| Powell, M | 1 |
| Enot, KJ | 1 |
| Garrett, MJ | 1 |
| Hughes, HJ | 1 |
| Ryall, RD | 1 |
| Hildebrand, J | 1 |
| Brihaye, J | 1 |
| Wagenknecht, L | 1 |
| Carter, SK | 1 |
| Engstrom, PF | 1 |
| Catalano, RB | 1 |
| Creech, RH | 1 |
| Baumöhl, J | 1 |
| Jurga, L | 1 |
| Klimo, J | 1 |
| Jutka, K | 1 |
| Zábranská, M | 1 |
| Lakhani, S | 1 |
| Selby, P | 1 |
| Bliss, JM | 1 |
| Perren, TJ | 1 |
| Gore, ME | 1 |
| McElwain, TJ | 1 |
| Le Chevalier, T | 1 |
| Arriagada, R | 1 |
| Quoix, E | 1 |
| Ruffie, P | 1 |
| Martin, M | 1 |
| Tarayre, M | 1 |
| Lacombe-Terrier, MJ | 1 |
| Douillard, JY | 1 |
| Laplanche, A | 1 |
| Cohen, SM | 1 |
| Ohnuma, T | 1 |
| Ambinder, EP | 1 |
| York, RM | 1 |
| Foltz, AT | 1 |
| Kühböck, J | 1 |
| Pötzi, P | 1 |
| Madaras, T | 1 |
| Young, DW | 1 |
| Lever, RS | 1 |
| English, JS | 1 |
| MacKie, RM | 1 |
| Marangolo, M | 1 |
| Pezzuoli, G | 1 |
| Marubini, E | 1 |
| Amadori, D | 1 |
| Boracchi, P | 1 |
| Cocconi, G | 1 |
| Cunsolo, A | 1 |
| Garcea, D | 1 |
| Germiniani, R | 1 |
| Luporini, G | 1 |
| Shelley, W | 1 |
| Quirt, I | 1 |
| Bodurtha, A | 1 |
| Iscoe, N | 1 |
| Russell, J | 1 |
| Paterson, A | 1 |
| Young, V | 1 |
| Jacobs, RH | 1 |
| Greenburg, A | 1 |
| Bitran, JD | 1 |
| Hoffman, PC | 1 |
| Albain, KS | 1 |
| Desser, R | 1 |
| Potkul, L | 1 |
| Golomb, HM | 1 |
| Chasen, MR | 1 |
| Falkson, G | 1 |
| van der Merwe, CA | 1 |
| Dreyer, RJ | 1 |
| Terblanche, AP | 1 |
| Eagan, RT | 1 |
| Frytak, S | 1 |
| Richardson, RL | 1 |
| Creagan, ET | 1 |
| Nichols, WC | 1 |
| Mohiuddin, M | 1 |
| Cantor, RJ | 1 |
| Biermann, W | 1 |
| Weiss, SM | 1 |
| Barbot, D | 1 |
| Rosato, FE | 1 |
| Page, JP | 1 |
| Levi, JA | 1 |
| Woods, RL | 1 |
| Tattersall, MN | 1 |
| Fox, RM | 1 |
| Coates, AS | 1 |
| Bajetta, E | 1 |
| Buzzoni, R | 1 |
| Viviani, S | 1 |
| Vaglini, M | 1 |
| Nava, M | 1 |
| Bonadonna, G | 1 |
| Oi, S | 1 |
| Matsumoto, S | 1 |
| Raimondi, AJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Trial of 5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT00359606] | Phase 1 | 58 participants (Actual) | Interventional | 1999-04-30 | Completed | ||
| Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine[NCT01479348] | Early Phase 1 | 5 participants (Actual) | Interventional | 2011-11-01 | Terminated (stopped due to Slow, insufficient accrual.) | ||
| A Phase II, Randomised Study of Nivolumab as Consolidation Therapy in Patients With Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent C[NCT04085250] | Phase 2 | 264 participants (Actual) | Interventional | 2019-11-28 | Active, not recruiting | ||
| Total-body PET/CT Imaging Using the uEXPLORER in Non-small Cell Lung Cancer Patients Treated by Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiotherapy[NCT04654234] | 20 participants (Anticipated) | Observational [Patient Registry] | 2020-09-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT01479348)
Timeframe: Date treatment consent signed to date off study, approximately 20 months and 12 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 2 |
[F-18]-5-fluoro-2'-deoxycytidine (FdCyd) was administered intravenously with administration of tetrahydrouridine (THU) and the frequency and severity of adverse events was observed. A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. Grade 0 is normal, Grade 1 is mild, Grade 2 is moderate, Grade 3 is severe or medically significant but not immediately life-threatening, Grade 4 is life-threatening consequences, and Grade 5 is death related to adverse event. (NCT01479348)
Timeframe: Within 5 days after interventions
| Intervention | adverse events (Number) | |||||
|---|---|---|---|---|---|---|
| Day 1 Adverse Events | Day 2, Grade 2 Hypoalbuminemia | Day 2, Grade 3 Anemia | Day 3 Adverse Events | Day 4 Adverse Events | Day 5 Adverse Events | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 0 | 1 | 1 | 0 | 0 | 0 |
Radiation dosimetry was determined based on the first patients. This involved making region of interest measurements on the scan for each major organ and measuring the uptake. Using standard dosimetry software this is converted into mSv/MBq, a standard measure of dosimetry. The software is known as Organ Level INternal Dose Assessment/EXponential Modeling (OLINDA) and is commonly used to generate this kind of data. (NCT01479348)
Timeframe: 1 year
| Intervention | mSv/MBq (Mean) | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adrenals | Brain | Breasts | Gallbladder wall | Lower large intestine wall | Small intestine | Stomach wall | Upper large intestine wall | Heart wall | Kidneys | Liver | Lungs | Muscle | Ovaries | Pancreas | Red marrow | Osteogenic cells | Skin | Spleen | Testes | Thymus | Thyroid | Urinary bladder wall | Uterus | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.83 | 8.17 | 1.03 | 4.05 | 2.52 | 2.13 | 1.90 | 2.04 | 1.10 | 5.26 | 6.02 | 1.82 | 1.16 | 1.57 | 1.63 | 1.14 | 1.71 | 8.65 | 1.69 | 1.03 | 1.12 | 8.23 | 7.96 | 1.63 |
Participants were scanned by positron emission tomography (PET) and lesions were measured at 4 time points after injection. (NCT01479348)
Timeframe: 9 minutes, 32 minutes, 56 minutes and 2 hours after injection
| Intervention | TBR ratio (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pt 1 L. Parotid adenosquam. cell ca at 9 min | Pt 1 L. Parotid adenosquam. cell ca at 32 min | Pt 1 L. Parotid adenosquam. cell ca at 56 min | Pt 1 L. Parotid adenosquam. cell ca at 2 hrs | Pt 2 R. Parapharyngeal Spindle Cell Ca at 9 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 32 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 56 min | Pt 2 R. Parapharyngeal Spindle Cell Ca at 2 hrs | Pt 3 Non-small Cell Lung Ca at 9 min | Pt 3 Non-small Cell Lung Ca at 32 min | Pt 3 Non-small Cell Lung Ca at 56 min | Pt 3 Non-small Cell Lung Ca at 2 hrs | Pt 4 Non-small Cell Lung Ca at 9 min | Pt 4 Non-small Cell Lung Ca at 32 min | Pt 4 Non-small Cell Lung Ca at 56 min | Pt 4 Non-small Cell Lung Ca at 2 hrs | Pt 5 Hepatocellular Ca at 9 min | Pt 5 Hepatocellular Ca at 32 min | Pt 5 Hepatocellular Ca at 56 min | Pt 5 Hepatocellular Ca at 2 hrs | |
| 1/Intravenous (IV) Tetrahydrouridine (THU) | 1.4 | 1.5 | 1.5 | 1.6 | 1.9 | 1.7 | 1.7 | 1.6 | 1.4 | 1.4 | 1.5 | 1.7 | 2.4 | 2.1 | 1.6 | 2.0 | NA | NA | NA | NA |
5 reviews available for lomustine and Metastase
| Article | Year |
|---|---|
Systemic chemotherapy in the treatment of malignant melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carmustine; Cisplatin; Clinical Trials as | 2003 |
Chemotherapy of esophageal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Doxorub | 1984 |
The current management of malignancy. IV.-Cancer of the lung.
Topics: Adenocarcinoma; Adrenocorticotropic Hormone; Adult; Carcinoma; Carcinoma, Bronchogenic; Carcinoma, S | 1975 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; | 1976 |
A pharmacologic basis for brain tumor chemotherapy.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Division; Doxorubicin; Drug Interactions; Huma | 1975 |
34 trials available for lomustine and Metastase
| Article | Year |
|---|---|
Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1-3) Medulloblastoma--a safety/feasibility study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Cerebellar Neoplasms; Chemoradiotherapy; | 2014 |
Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.
Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Brain Neoplasms; Humans; Lomustine; Neoplas | 1972 |
Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 2002 |
Low-dose continuous chemotherapy for metastatic melanoma: a phase II trial.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylatin | 2003 |
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Disease-Free Su | 2003 |
Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 2005 |
Continuous versus alternating combination chemotherapy for advanced small cell carcinoma of the lung.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Cyc | 1983 |
Combination chemotherapy in metastatic or recurrent non-small cell bronchogenic carcinoma. 5-year results.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Bronchogenic; Clinical Trial | 1983 |
Combination chemotherapy with 5-fluorouracil, CCNU, and vincristine in metastatic colorectal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neopl | 1984 |
Mitomycin-C, etoposide, cisplatin, and hexamethylmelamine (MEPH) as a second-line regimen in lung cancer.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy | 1984 |
Treatment of patients with metastatic melanoma with a one day regimen of dacarbazine, vincristine, bleomycin and lomustine plus interferon-alpha.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Female; Humans; | 1994 |
Intermittent interferon and polychemotherapy in metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administra | 1995 |
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano | 1994 |
Tumor-infiltrating lymphocytes in patients with metastatic melanoma receiving chemoimmunotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bleomycin; CD4-CD8 Ratio; Combi | 1997 |
Single-agent therapy for renal cell carcinoma: CCNU, vinblastine, thioTEPA, or bleomycin.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Drug Evaluation; Female; Humans; Kidney Neoplasms; | 1977 |
CCNU, bleomycin, and methylprednisolone with or without adriamycin in renal cel carcinoma: a randomized trial.
Topics: Adenocarcinoma; Antineoplastic Agents; Bleomycin; Doxorubicin; Drug Therapy, Combination; Female; Hu | 1977 |
Phase II trial with bleomycin, CCNU, and streptozotocin in patients with metastatic cancer of the breast.
Topics: Adult; Aged; Bleomycin; Bone Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Evaluation; | 1977 |
Use of combination chemotherapy with CCNU, bleomycin, and vincristine in the treatment of metastatic melanoma in patients resistant to DTIC therapy.
Topics: Adult; Aged; Bleomycin; Clinical Trials as Topic; Dacarbazine; Drug Resistance; Drug Therapy, Combin | 1979 |
Chemotherapy of gastric and pancreatic carcinoma: a controlled evaluation of combinations of 5-fluorouracil with nitrosoureas and "lactones".
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Therapy, Combination; Fluorouracil; Humans; Lomustine; N | 1979 |
Treatment of malignant gliomas and brain metastases in adults using a combination of adriamycine, VM 26, and CCNU. Results of a type II trial.
Topics: Adult; Aged; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Therapy, | 1977 |
Multidisciplinary treatment for central nervous system tumours with nitrosourea compounds.
Topics: Adolescent; Adult; Aged; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Lomu | 1978 |
Chemotherapy for colorectal cancer with 5-fluorouracil, cyclophosphamide, and CCNU: comparison of oral and continuous iv administration of 5-fluorouracil.
Topics: Administration, Oral; Adult; Clinical Trials as Topic; Colonic Neoplasms; Cyclophosphamide; Drug Eva | 1978 |
CCNU, vinblastine, and delalutin therapy in renal cell carcinoma.
Topics: Adenocarcinoma; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Humans; Hydrox | 1978 |
Prophylactic cranial irradiation in small cell carcinoma of the lung. A randomized study.
Topics: Adult; Aged; Brain; Brain Neoplasms; Carcinoma; Cyclophosphamide; Doxorubicin; Drug Therapy, Combina | 1977 |
DTIC (NSC-45388) in malignant melanoma: a perspective.
Topics: Animals; Antineoplastic Agents; Carmustine; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; | 1976 |
Methyl-CCNU (NSC-95441) in advanced colorectal carcinoma after failure of 5-fluorouracil (NSC-19893) therapy.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Clinical Trials as Topic; Colonic Neoplasms; | 1976 |
[Trial treatment of glioblastomas in adults and cerebral metastais by adriamycin, VM 26 and CCNU combination. Result of a type II trial].
Topics: Adult; Aged; Brain Neoplasms; Clinical Trials as Topic; Doxorubicin; Drug Evaluation; Drug Therapy, | 1976 |
Preliminary report on the use of CCNU (NSC-79037), adriamycin (NSC-123127), and hexamethylmelamine (NSC-13875) in carcinoma of the lung.
Topics: Adult; Aged; Altretamine; Carcinoma, Squamous Cell; Clinical Trials as Topic; Doxorubicin; Drug Eval | 1976 |
5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer.
Topics: Drug Evaluation; Fluorouracil; Humans; Leukopenia; Lomustine; Male; Neoplasm Metastasis; Nitrosourea | 1977 |
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1991 |
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1991 |
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1991 |
Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined | 1991 |
Adjuvant chemotherapy with fluorouracil and CCNU in colon cancer. Results of a multicentric randomized study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colonic Neoplasms; C | 1989 |
Combined modality treatment of localized unresectable adenocarcinoma of the pancreas.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Clinical Trials as To | 1988 |
Randomized trial of combination chemotherapy in hormone-resistant metastatic prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamide; Do | 1985 |
Prospective randomized trial in advanced malignant melanoma with cis-platinum, vindesine, and etoposide vs. cis-platinum, vindesine, and lomustine.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic | 1985 |
47 other studies available for lomustine and Metastase
| Article | Year |
|---|---|
Bacterial Sepsis Increases Survival in Metastatic Melanoma: Chlamydophila Pneumoniae Induces Macrophage Polarization and Tumor Regression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Chlamydophila Infections; Chlamy | 2016 |
Long-term survival in dogs with localized histiocytic sarcoma treated with CCNU as an adjuvant to local therapy.
Topics: Animals; Antineoplastic Agents; Chemotherapy, Adjuvant; Cohort Studies; Disease-Free Survival; Dog D | 2009 |
[Chemotherapy of malignant solid tumors].
Topics: Bleomycin; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Fluorouracil; Humans; Kidney Neo | 1980 |
Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung: the results at 36 months. 2nd report to the Medical Research Council on the 2nd small-cell study.
Topics: Aged; Carcinoma, Small Cell; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lomustine; | 1981 |
Changes in T and B lymphocyte subpopulations before, during and after chemotherapy for malignant melanoma.
Topics: Aged; B-Lymphocytes; Dacarbazine; Female; Humans; Leukocyte Count; Lomustine; Lymphocytes; Male; Mel | 1984 |
Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lomu | 1984 |
A critical review of immunotherapy of disseminated renal adenocarcinoma.
Topics: Adenocarcinoma; BCG Vaccine; Drug Evaluation; Drug Therapy, Combination; Humans; Kidney Neoplasms; L | 1982 |
Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Humans; Lomustine; | 1980 |
Medical treatment of metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Drug Therapy, Combination; Female; Hormones; Humans; Kidney Neop | 1980 |
The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; CD4-CD8 Ratio; Dacarbazine; | 1996 |
Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay--can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined | 1996 |
The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined C | 1998 |
Bleomycin in testicular teratomas.
Topics: Adult; Bleomycin; Choriocarcinoma; Drug Therapy, Combination; Follow-Up Studies; Humans; Lomustine; | 1975 |
Nonhormonal chemotherapy for disseminated renal cell carcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bleomycin; Female; Humans; Kidney Neoplasms; Lomustine; | 1976 |
Combined therapy with bleomycin against malignant melanomas and testicular tumors.
Topics: Abdominal Neoplasms; alpha-Fetoproteins; Bleomycin; Carcinoembryonic Antigen; Drug Administration Sc | 1976 |
Combination chemotherapy with three marginally effective agents, CCNU, vincristine, and bleomycin, in the treatment of stage III melanoma.
Topics: Adolescent; Adult; Aged; Bleomycin; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lomu | 1976 |
Hypercalcemia in small cell (oat cell) carcinoma of the lung. Coincident parathyroid adenoma in one case.
Topics: Adenoma; Adult; Bone Neoplasms; Calcitonin; Carcinoma, Small Cell; Cyclophosphamide; Furosemide; Hum | 1975 |
Prevention of brain extension in small-cell carcinoma of the bronchus.
Topics: Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Carcinoma, Small Cell; Drug Therapy, Co | 1978 |
Large cell bronchogenic carcinoma. Prolonged disease-free survival following chemotherapy.
Topics: Carcinoma, Bronchogenic; Carcinoma, Small Cell; Humans; Lomustine; Lung Neoplasms; Male; Middle Aged | 1979 |
Schedule dependent effectiveness of CCNU and 5-fluorouracil in experimental chemotherapy.
Topics: Animals; Cell Survival; Drug Therapy, Combination; Fluorouracil; Hematopoietic Stem Cells; Lomustine | 1977 |
Chemoimmunotherapy of metastatic large bowel cancer: nonspecific stimulation with BCG and levamisole.
Topics: BCG Vaccine; Colonic Neoplasms; Drug Therapy, Combination; Fluorouracil; Humans; Levamisole; Lomusti | 1977 |
[Clinical and therapeutic study (phase II) using VP-16/213 and methyl-CCNU in patients with inoperable, recurring or metastasizing carcinomas of the gastriointestinal tract].
Topics: Adult; Aged; Colonic Neoplasms; Drug Therapy, Combination; Etoposide; Female; Follow-Up Studies; Hum | 1978 |
Chemotherapy of experimental metastatic brain tumors in female Wistar rats.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma 256, Walker; Carotid Arteries; Cells, Cul | 1979 |
Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer.
Topics: Adult; Aged; Bone Marrow; Brain Neoplasms; Breast Neoplasms; Doxorubicin; Drug Therapy, Combination; | 1978 |
Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
Topics: BCG Vaccine; Blood Cell Count; Dacarbazine; Drug Therapy, Combination; Humans; Immunotherapy; Lomust | 1976 |
Single drug and combination chemotherapy in the treatment. Disseminated malignant melanoma.
Topics: Antineoplastic Agents; Carmustine; Dacarbazine; Drug Therapy, Combination; Humans; Hydroxyurea; Lomu | 1977 |
Combination chemotherapy with CCNU, melphalan, methotrexate, and prednisone (CAMP) in 35 patients with advanced breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combinatio | 1977 |
Meningeal carcinomatosis. Case report and review of the literature.
Topics: Adult; Brain Neoplasms; Breast Neoplasms; Carcinoma; Female; Humans; Lomustine; Meninges; Methotrexa | 1976 |
[Chemotherapy in primary and metastatic intrathoracic cancer].
Topics: Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cyclophosphamide; Doxorubicin; Drug Th | 1976 |
Treatment of malignant gliomas and brain metastases in adults with a combination of adriamycin, VM 26, and CCNU. Results of a phase II trail.
Topics: Adult; Aged; Brain Neoplasms; Doxorubicin; Drug Therapy, Combination; Drug Tolerance; Female; Glioma | 1976 |
Growth rate of pulmonary metastases in human sarcomas.
Topics: Adolescent; Adult; Aged; Bone Neoplasms; Child; Female; Fibrosarcoma; Hemangiopericytoma; Humans; Le | 1975 |
Phase II study of procarbazine, CCNU, and vincristine combination chemotherapy in the treatment of malignant brain tumors.
Topics: Brain Neoplasms; Drug Therapy, Combination; Evaluation Studies as Topic; Humans; Lomustine; Neoplasm | 1975 |
CCNU in brain tumours.
Topics: Adolescent; Adult; Brain Neoplasms; Bronchial Neoplasms; Cerebellar Neoplasms; Child, Preschool; Fem | 1975 |
Combination chemotherapy with CCNU, vincristine and methotrexate in primary and metastatic brain tumors.
Topics: Brain Neoplasms; Drug Therapy, Combination; Humans; Lomustine; Methotrexate; Neoplasm Metastasis; Ni | 1975 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Editorial: Large-bowel cancer-The current status of treatment.
Topics: Adjuvants, Immunologic; BCG Vaccine; Carmustine; Colonic Neoplasms; Doxorubicin; Drug Therapy, Combi | 1976 |
Phase II study of methyl-CCNU (NSC-95441) in advanced gastrointestinal cancer.
Topics: Adenocarcinoma; Adult; Aged; Blood Platelet Disorders; Drug Evaluation; Female; Gastrointestinal Neo | 1976 |
Combined chemotherapy (cisplatin, cyclophosphamide, lomustine and vincristine) and multifractionation radiotherapy in inoperable nonmetastatic squamous cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modali | 1992 |
Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleo | 1990 |
Lomustine, bleomycin, and cisplatin in patients with metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cisplatin; Drug Evaluation; | 1986 |
Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Humans; Lomustine; Melanoma; | 1988 |
Palliative and adjuvant chemotherapy of metastatic renal cancer.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Female; Hu | 1988 |
The use of BELD combination chemotherapy (bleomycin, vindesine, CCNU, and DTIC) in advanced malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazine; Drug Administra | 1985 |
Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; L | 1985 |
A 10-year experience with combined modality therapy for stage III small cell lung carcinoma.
Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modalit | 1986 |
Prognostic factors in patients with small-cell carcinoma of the lung.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cyclophosphamide | 1986 |
Phase II study of the three-drug combination of mitomycin C, CCNU, and methotrexate (MCM) in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Evaluation; Female; Humans; Lomust | 1986 |
[Brain tumors in infants and children--factors affecting prognosis, (Part-3). Mode of metastasis and prognosis in medulloblastoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Brain Stem; Cerebellar Neoplasms; C | 1985 |